Innatoss Laboratories
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €550k | Seed | |
N/A | €380k | Seed | |
N/A | €300k | Early VC | |
N/A | €50.0k | Grant | |
N/A | €400k | Convertible | |
€860k | Grant | ||
N/A | Early VC | ||
Total Funding | €2.5m |
Recent News about Innatoss Laboratories
EditInnatoss Laboratories specializes in innovative diagnostics for infectious diseases, focusing on conditions such as Lyme disease, COVID-19, and Q fever. The company operates in the healthcare diagnostics market, serving medical professionals, healthcare institutions, and patients who require accurate and early detection of these diseases. Innatoss employs advanced diagnostic technologies to develop tests that are more sensitive and specific than traditional methods. The business model revolves around the development, validation, and commercialization of diagnostic tests, generating revenue through the sale of these tests to healthcare providers and institutions. Innatoss also collaborates with research organizations and receives grants to further its diagnostic capabilities and personalize treatments. The company aims to improve patient outcomes by providing reliable and timely diagnostic solutions.
Keywords: diagnostics, infectious diseases, Lyme disease, COVID-19, Q fever, healthcare, medical professionals, advanced technology, patient outcomes, research collaboration.